ERBB2 and interstitial lung disease: More importantly, interstitial lung disease (namely is pneumonitis) was previously described as a rare but common AEs in some anti-HER2 drugs, involving trastuzumab(9.9%), lapatinib (0.2%), T-DM1 (0.5%), DS-8201 (9.0%), and trastuzumab duocarmazine (7.7%) (Hackshaw et al., 2020; Shitara et al., 2020).